Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2009

View Archived Issues

NuPathe reports phase III results for Zelrix transdermal patch for migraine

FDA Advisory Committee recommends GE Healthcare's DaTSCAN

Ikaria to in-license worldwide rights to investigational fibrin-derived peptides

Javelin reports phase III results for intranasal ketamine in pain

Genmab presents preliminary topline results for Arzerra in CLL

Nycomed and Forest to collaborate on roflumilast for COPD

In vivo pharmacokinetics and metabolism data on afobazole presented at EACPT

Squalene synthase inhibitors display preclinical anti-atherosclerotic activity in recent study

Dako collaborates with Genentech on diagnostic tests for gastric cancer

PARP inhibitor PJ-34 reduces tPA-induced intracerebral hemorrhage in ischemic mice

Novel VEGF inhibitor NP-184 displays anti-angiogenic activity in preclinical study

Antithrombotic effects and improved safety shown by AVE-5026 in animal models

Wyeth receives notice from FDA for extended Prevnar 13 action date

Preliminary phase I and I/II data suggest safety and clinical activity of IMGN-901 in SCLC

Multaq approved in Canada for atrial fibrillation

Opexa enters into stem cell agreement with Novartis

Forest and AstraZeneca to codevelop and commercialize ceftaroline

Abbott discloses histamine H3 receptor ligands for the treatment of ADHD

Kissei describes COMT inhibitors for the treatment of Parkinson's disease

S1P1 receptor agonists in development at GSK

Sanofi-aventis synthesizes P2Y12 receptor antagonists useful in antiplatelet therapy

Novel vitamin D3 derivatives reported for the treatment of psoriasis

Shanghai Hengrui claims DDP IV inhibitors for the treatment of diabetes

ALK5 inhibitors in early development at Novartis for the treatment of PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...